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Summary 
 
     Upon entry into the central nervous system (CNS), serum insulin-like growth factor-1 
(IGF-I) modulates neuronal growth, survival and excitability. Yet mechanisms that trigger 
IGF-I entry across the blood-brain barrier remain unclear. We show that neuronal activity 
elicited by electrical, sensory or behavioral stimulation increases IGF-I input in activated 
regions. Entrance of serum IGF-I is triggered by diffusible messengers (i.e. ATP, 
arachidonic acid derivatives) released during neuro-vascular coupling. These messengers 
stimulate matrix metalloproteinase-9, leading to cleavage of the IGF binding protein-3 
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(IGFBP-3). Cleavage of IGFBP-3 allows the passage of serum IGF-I into the CNS through 
an interaction with the endothelial transporter lipoprotein related receptor 1. Activity-
dependent entrance of serum IGF-I into the CNS may help to explain disparate 
observations such as pro-neurogenic effects of epilepsy, rehabilitatory effects of neural 
stimulation and modulatory effects of blood flow on brain activity. 
 
 
Introduction 
 
     The blood-brain-barriers (BBB) located at brain vessels and choroid plexuses regulate 
passage of blood constituents into the brain parenchyma and cerebrospinal fluid (CSF), 
respectively (Abbott et al., 2010). Once considered an almost impermeable barrier for 
serum proteins, it is now apparent that many circulating hormones and growth factors can 
cross the BBB through specific transport mechanisms that usually involve their cognate 
receptors (Banks, 2006). However, the physiological significance of this blood-to-brain 
traffic of hormones and growth factors remains uncertain.  
     Insulin-like growth factor I (IGF-I), a peptide with ample neuroprotective activity 
(Russo et al., 2005), is one of the growth factors found to enter the brain from the 
circulation (Pardridge, 1993; Carro et al., 2000; Pulford and Ishii, 2001; Reinhardt and 
Bondy, 1994). Circulating IGF-I is produced mostly by the liver and is an important 
mediator of growth hormone actions in body growth and tissue remodelling . In addition, 
serum IGF-I shows a wide neuroactive profile that hints to an important role in brain 
homeostasis. Thus, blood-borne IGF-I modulates brain vessel growth (Lopez-Lopez et al., 
2004), adult neurogenesis (Aberg et al., 2000), neuronal excitability (Nunez et al., 2003), or 
even cognitive function (Trejo et al., 2007). Collectively these observations provide a 
strong rationale for the need of circulating IGF-I to cross the BBB. Notably, the BBB 
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architecture is well suited to transport serum IGF-I into the brain as both brain vessels and 
glial end-feet surrounding them express IGF-I receptors (Garcia-Segura et al., 1991). If 
IGF-I is transferred by endothelial cells into the perivascular space, surrounding glial end-
feet from astrocytes, able to endocytose IGF-I (Auletta et al., 1992), could transfer IGF-I to 
adjacent neurons through trans-endocytosis or a related process. Indeed, while upon 
binding to its membrane receptor IGF-I is internalized and mostly degraded (Geary et al., 
1989), several cell types can translocate intact IGF-I to other cell compartments or even 
export it outside the cell (Zapf et al., 1994).  
     The choroid plexus epithelium at the blood-CSF interface also express high levels of 
IGF-I receptors (Marks et al., 1991). In previous work we found that increases in systemic 
IGF-I led to increased passage into the CSF through a mechanism involving the multicargo 
protein transporter low density lipoprotein receptor related protein 2 (LRP2) located in this 
sealed epithelium (Carro et al., 2000;Carro et al., 2005). Therefore, a tonic transfer of 
serum IGF-I into the CSF may be explained by physiological oscillations in blood IGF-I 
levels (Carro et al., 2000). However, serum IGF-I levels usually remain very steady. Thus, 
a mechanism involving regulated passage of serum IGF-I may also co-exist with this tonic 
input. A possible regulatory mechanism independent of changes in serum IGF-I levels may 
be activity-driven.  
     Brain activity dictates transfer of oxygen and nutrients from the circulation into 
activated regions through a “neuro-vascular coupling” process described long ago (Roy and 
Sherrington, 1890). This process recruits all the cellular components of the neuro-vascular 
unit, with astrocytes serving an important intermediary role between neuronal activation 
and endothelial transport of oxygen and glucose (Zonta et al., 2003). While the intracellular 
pathways involved in neuro-vascular coupling are not fully understood, a wealth of data 
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indicate that diverse mediators released in response to neuronal glutamate (arachidonic acid 
derivatives, ATP...etc) influence the microcirculation allowing local increased passage of 
glucose and other nutrients through brain endothelial cells.   
     IGF-I in blood travels as a complex with an insulin-like binding protein 3 (IGFBP-3) 
and an “acid labile subunit” chaperone that regulates availability to target tissues by 
regulated release of IGF-I. Although the details of the trans-endothelial transport of IGF-I 
are not known, the tertiary complex probably tethers/associates to blood vessels to deliver 
IGF-I to endothelial cells after cleavage of IGFBP-3 by proteases. IGFBP-3 associates to 
the extracellular matrix and to membrane proteins such as LRP1. This membrane cargo-
transporter mediates transcytosis of ligands across brain endothelial cells and has been 
postulated to be a cellular receptor for IGFBP-3 (Huang et al., 2003). LRP1 is abundantly 
expressed in brain endothelium and interacts with the insulin receptor (Bilodeau et al., 
2009), which is closely related to the IGF-I receptor. Altogether, these characteristics make 
LRP-1 an attractive candidate to serve as a targeting platform for the circulating IGF-
I/IGFBP-3 complex.  
     In the present work we explored whether brain activity modulates entrance of serum 
IGF-I and possible mechanisms involved. We observed that serum IGF-I input to the brain 
is regulated by an activity-driven process that includes changes in BBB permeability to 
serum IGF-I. This process is initiated by the release of glutamate at active regions. 
Thereafter, two parallel processes are set in motion; vasodilation to increase local 
availability of serum IGF-I, and increased activity of matrix metalloprotease 9 (MMP9), an 
IGFBP3 protease already reported to be released in response to neuronal activity (Michaluk 
and Kaczmarek, 2007). The combined action of these two processes result in increased 
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local availability of free serum IGF-I that is transcytosed through an LRP1-dependent 
mechanism. 
 
Results 
Neuronal activity stimulates uptake of serum IGF-I.  
     To assess mechanisms by which IGF-I might penetrate the BBB in response to neuronal 
activity we used a combination of experimental approaches. First, we placed a stimulating 
electrode in the inferior cerebellar peduncle of rats receiving a bolus injection of human 
recombinant IGF-I (hIGF-I; 10µg/100g) in the carotid artery immediately before 
stimulation. Using a human-specific IGF-I ELISA we distinguished between exogenous 
and endogenous (rat brain) IGF-I. As previously documented (Carro et al., 2000), hIGF-I 
was detected in different brain regions after systemic delivery. However, electrical 
stimulation (15 min, 5 Hz) of the cerebellar peduncle elicited an additional significant 
increase in cerebellar hIGF-I levels (Figure 1A). Non-stimulated regions such as the 
cerebral cortex did not show differences between stimulated and sham-stimulated animals 
(Figure 1A).  
     To assess whether systemic IGF-I accumulates in active brain areas regardless of region 
and type of stimulus, we activated the rat somatosensory cortex by unilateral whisker 
stimulation (60 min, 2 or 5 Hz). As seen in Figure 1B, stimulation of the vibrissae at 2 Hz 
effectively activated cortical somatosensory neurons, whereas at 5 Hz stimulation was 
dumped (inset) due to neuronal desensitization (Chung et al., 2002). Accordingly, only 
stimulation of the whiskers at 2 Hz increased hIGF-I in somatosensory cortex as compared 
to animals stimulated at 5 Hz, or sham-stimulated animals (Figure 1B). Frequency-
dependence uptake of IGF-I by the brain correlates with frequency-dependent changes in 
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cerebral blood flow in the barrel cortex  during whisker stimulation (see below). These 
observations further confirmed that entrance of systemic IGF-I is regulated by neuronal 
activity. A region unrelated to the stimulation site such as the olfactory bulb, that had 
relatively high levels of hIGF-I after systemic injection, did not show stimulus-dependent 
increases in hIGF-I (not shown). Local IGF-I synthesis was not modified by stimulation; 
IGF-I mRNA levels in the stimulated somatosensory cortex did not differ from those in the 
unstimulated side (Fig S1A). Further, the IGF-I receptor was more activated in the 
stimulated than in the non-stimulated somatosensory cortex, as determined by increased 
levels of the Tyr-phosphorylated form of the receptor (Figure 1C). The latter confirms 
increased IGF-I input in the stimulated area. 
     We next assessed whether natural alterations in brain activity patterns, resulting from 
normal behavioral patterns, regulate IGF-I entry into the CNS. Mice submitted to a brief 
episode (2 hours) of environmental enrichment including multiple sensori-motor stimuli 
and increased social engagement showed a 60% increase in hippocampal  IGF-I levels 
compared to animals staying in their normal cages (Figure 1D). In addition, 
phosphorylation levels of hippocampal IGF-I receptor were significantly higher after 
environmental enrichment (Figure 1E). Thus, IGF-I input to this brain area appears 
augmented by environmental enrichment.  
     As systemic administration of IGF-I modulates basal neuronal excitability (Nunez et al., 
2003), we determined whether IGF-I also influences neuronal output in stimulated brain 
areas. Infusion of the IGF-I receptor antagonist PPP in the somatosensory cortex during 
unilateral tactile stimulation of the whiskers significantly reduced neuronal activation in 
this area. Under control conditions, whisker deflections (20 ms duration) induced spike 
firing in the primary somatosensory cortex of 2.9 spikes/stimulus (Figure 1F). However, 
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intracortical application of PPP (2.5 µM) reduced cortical responses to 2.2 spikes/stimulus 
15 min after application (p=0.005), and to 1.9 spikes/stimulus 30 min later (Figure 1F, 
lower panel; n= 19 cells; p=0.004). These results strongly suggest that IGF-I input into 
active brain regions has a functional impact.  
Activity-dependent entrance of serum IGF-I across brain vessels. 
     Albeit at lower levels, non-stimulated brain areas also accumulate hIGF-I after 
intracarotid injection (i.e.: cortex in Figure 1A). Hence, we next determined whether 
systemic hIGF-I entered into the brain after neuronal activation through the blood-CSF 
interface (Carro et al., 2000). We assessed levels of hIGF-I in CSF after whisker 
stimulation and found no changes as compared to non-stimulated animals (Fig S1B). This 
suggested that activity-dependent entrance of systemic hIGF-I occurs through a different 
pathway. In agreement with this, when hIGF-I (5 µg/rat) was directly delivered into the 
CSF (Fig S1C), no stimulus-dependent increases of hIGF-I in the activated somatosensory 
cortex were seen (Fig S1D). This also indicated that cerebrospinal fluid IGF-I does not 
redistribute to active brain regions. Hence, the other possible route of entrance of 
circulating IGF-I into active brain areas is the local vasculature. Indeed, administration of 
digoxigenin-labelled IGF-I (Dig-IGF-I) immediately before stimulation of the whiskers or 
the sciatic nerve resulted in specific digoxigenin immunostaining in the stimulated side of 
the somatosensory cortex (Figure 2A). Double immunostaining with cell-specific markers 
showed that Dig-IGF-I staining colocalized with brain vessels (lectin
+
 cells), astrocytes 
(GFAP
+
), and neurons (β3tubulin
+
) (Figure 2B). Cells with neuronal morphology co-stained 
for digoxigenin and IGF-I, indicating that digoxigenin remained attached to IGF-I (Fig 
S2A). Non-stimulated animals did not show immunoreactivity in somatosensory cortex 
(Figure 2A, panel b). Further, Dig-IGF-I staining was also prominent in the posterio-medial 
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thalamus (Figure 2C) contralateral to the stimulated whisker pad. As this thalamic relay is 
within the whisker-cortex pathway this suggests an spatial overlap between activated areas 
and IGF-I uptake. In this regard, neuronal activation determined by c-fos immunoreactivity 
showed overlapping of Dig-IGF-I staining with active brain regions within this sensory 
pathway such as the sensitive nucleus of the trigeminal nerve, the lateral thalamus and the 
primary somatosensory cortex (Figure 2D). Electron microscopy analysis combined with 
immunogold labelling confirmed the presence of Dig-IGF-I  in various cell compartments 
of brain vessels and neurons (Figure 3). Staining was observed in the cell nucleus, 
mitochondria and cytoplasm.  
Neuro-trophic coupling through activity-dependent mediators.  
     We next searched for mechanisms underlying activity-dependent entrance of systemic 
IGF-I through the brain vasculature. We focused on neuro-vascular coupling as it involves 
activity-dependent signalling from active synapses that modulate neighbouring blood 
vessels to enhance local blood flow. As expected, unilateral electrical stimulation of the 
whisker pad enhanced regional cerebral blood flow (CBF) in the activated somatosensory 
cortex (Figure 4A). Increases in CBF were frequency-dependent. Whereas stimulation at 2 
Hz consistently raised it, at 5 Hz only a transient increase was observed (Figure S3A). This 
observation linked neuronal blood flow with IGF-I entrance as at 5Hz no increases in hIGF-
I entrance were appreciated (Figure 1B). Blood pressure, body temperature and other 
systemic parameters (PCO2, PO2..etc) remained stable during stimulation of the animals 
(Table 1). No changes were observed in CBF at the unstimulated barrel cortex (not shown). 
As IGF-I may act as a vasodilator, we determined whether intracarotid administration of 
IGF-I alters CBF in somatosensory cortex of non stimulated animals, and found no changes 
(Fig S3B).                 
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     Confirming the above observations, hIGF-I levels were significantly elevated in brain 
interstitial fluid collected through a microdialysis probe placed in the somatosensory cortex 
of animals receiving vibrissae stimulation at 2 Hz (p<0.01; Figure 4B). Using this approach 
we determined the role of neuronal activity and vasodilation in activity-dependent IGF-I 
uptake. Intra-cortical infusion of TTX to inhibit neuronal activity (markedly reducing 
stimulus-induced increases in CBF, see Figure S3C), abrogated the increase in hIGF-I 
levels induced by vibrissae stimulation (Figure 4B). Similarly, infusion of the NO synthase 
inhibitor L-NAME to block vasodilation (that also results in diminished CBF after whisker 
stimulation, see Fig S3C), also abrogated this increase (Figure 4B). Collectively, these 
results indicate that both enhanced neuronal activity and increased blood flow are necessary 
for activity-dependent increases in serum IGF-I input to the brain.      
     As passage of serum IGF-I through blood-brain-barrier cells may involve all the cells 
forming the neurovascular unit,  we then used an in vitro system to determine whether the 
three main types of cells potentially involved in this purported blood-to-brain trafficking of 
IGF-I can internalize it. We found that endothelial cells, astrocytes, and neurons internalize 
intact biotinylated hIGF-I (bhIGF-I) after adding it to the culture medium (Figure 5A, upper 
blot). Elimination of non-specific protein binding to the cell membrane prior to cell lysis by 
acid wash confirmed that the 3 types of cells internalize bhIGF-I (Figure 5A, lower blots). 
Further, as shown in Figure 5A, double immunostaining of biotin-labelled IGF-I and cell-
specific markers show bhIGF-I immunoreactivity in endothelial cells (lectin
+
 cells), 
astrocytes (GFAP
+
), and neurons (β3tubulin
+
). We then hypothesized that once IGF-I binds 
to its receptors in endothelial cells, it will be internalized and translocated to adjacent glial 
end-feet surrounding brain vessels through a transcytosis process. To analyze this point we 
used a double chamber culture system with astrocytes as a feeder layer of endothelial cells 
 10 
in the upper chamber, and neurons placed in the lower chamber to mimic the BBB 
architecture. Under these conditions bhIGF-I was transported from the upper (i.e.: apical 
side or “blood side”of the endothelial monolayer) to the lower chamber (basolateral side or 
“brain side”) where neurons accumulated it (Figure 5B).    
     Next, we determined whether IGFBP-3 modulates internalization of IGF-I by 
endothelial cells. In the presence of IGFBP-3 (15 ng/ml) a weak, but significant decrease in 
bhIGF-I endocytosis by brain endothelial cell cultures was observed (Figure 5C). The 
modest effect of exogenous IGFBP-3 could be due to the presence of endogenous IGFBP-3, 
as endothelial cells produce this binding protein (Lee et al., 1999). Indeed, IGFBP-3 was 
detected in the cultures (Figure 5D). To further substantiate a role of this binding protein in 
internalization of IGF-I by brain endothelial cells we determined whether prostate specific 
antigen (PSA), an IGFBP-3 protease, affected internalization of  bhIGF-I. Addition of PSA 
greatly increased internalization of bhIGF-I by endothelial cells (Figure 5C). As the effect 
was antagonized by IGFBP-3 (Figure 5C) this further supports its involvement. Further, 
endocytosis of bhIGF-I required the IGF-I receptor. Either transfection of human 
endothelioma cells with a dominant-negative IGF-I receptor (Figure 5E) or incubation of 
brain endothelial cells with the IGF-I receptor antagonist PPP blocked IGF-I internalization 
(Figure S4A).  
     Because PSA is a prostate protease unlikely to be produced by brain cells, we searched 
for alternative protease(s) involved in IGFBP-3 cleavage in brain endothelium. Among 
potential candidates we chose matrix metalloproteinase-9 (MMP9). MMP9 not only cleaves 
this binding protein (Manes et al., 1999) (Figure 5F), but is present in brain endothelium 
(Wang et al., 2006), and, most significantly, is modulated by brain activity (Michaluk and 
Kaczmarek, 2007). In the presence of active, but not inactive MMP9 (50 ng/ml), brain 
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endothelial cells endocytosed significantly more bhIGF-I. The effect was inhibited by 
IGFBP-3 (p<0.001; Figure 5C). In contrast, another metalloprotease such as MMP8 did not 
increase IGF-I internalization by endothelial cells (Figure S4B). That another IGFBP-3 
protease increased basal endocytosis confirmed that endothelial IGFBP-3 is interfering with 
bhIGF-I endocytosis in our cultures. 
     To gain further insight into the mechanism underlying transcytosis of IGF-I we used the 
double chamber system mimicking the BBB, omitting neurons in the lower chamber to 
avoid IGF-I uptake. Under these conditions bhIGF-I was transported from the upper (i.e.: 
apical side or “blood side”of the endothelial monolayer) to the lower chamber (basolateral 
side or “brain side”), and its transport was significantly reduced when IGFBP-3 was added 
to the upper chamber (p<0.05; Figure 6A). Confirming the effects seen in endothelial cell 
cultures, MMP9 also induced transcytosis of bhIGF-I through endothelial-astrocyte co-
cultures, an effect blocked by IGFBP-3 (p<0.01; Figure 6A). 
     A key aspect of our proposal is that neuronal activation triggers serum IGF-I 
transcytosis from the blood into the brain. Glutamate released during neuronal activation 
signals to surrounding astrocytes (Haydon and Carmignoto, 2006;Perea et al., 2009) that in 
turn release vasoactive mediators (Iadecola and Nedergaard, 2007;Zonta et al., 2003). 
Accordingly, when glutamate (100 µM) was placed in the lower chamber (the brain side) of 
endothelial-astrocyte co-cultures, IGF-I transcytosis from the upper (the  blood side) to the 
lower chamber was greatly stimulated (p<0.01; Figure 6B). The stimulatory action of 
glutamate was fully abolished by an MMP9 inhibitor, reinforcing a role for this protease in 
transcytosis of IGF-I (Figure 6B). Moreover, MMP9 was readily detected in endothelial 
cells (Figure 6C, upper blots) and glutamate stimulated it in endothelial-astrocyte co-
cultures (Figure 6C). In agreement with this, and as expected for a protease that is 
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stimulated by brain activity (Michaluk and Kaczmarek, 2007), active MMP9 was increased 
in the stimulated somatosensory cortex (Figure 6D).  
     Next, we tested various vasoactive mediators proposed to be released in response to 
glutamate (Iadecola and Nedergaard, 2007). Among these, we chose those previously 
reported to enhance MMPs activity. The arachidonic acid derivatives prostaglandin E2 
(PGE2) and 11,12 epoxyeicosatrienoic acid (EET), together with ATP, but not NO, 
increased bhIGF-I endocytosis by endothelial cells (Figure 7A). Another EET derivative, 
8,9 EET, with lower vasodilatory activity (Harder et al., 1998) elicited a slightly smaller 
response: 70 ± 13% of the that seen with 11,12 EET. Confirming these in vitro observations, 
infusion of a pharmacological dose of PGE2 (5 mM) into the rat cerebral cortex (-0.5 mm 
from bregma, 1 mm depth) elicited widespread uptake of systemic digoxigenin-labelled 
IGF-I in the infused side (Figure 7B). Moreover, levels of PGE2 in stimulated 
somatosensory cortex increased to 4.2 ± 0.01 pg/ml from 1.9 ± 0.01 pg/ml seen in sham-
stimulated cortex (p<0.01, n=5 per group). While these levels are well below the 
pharmacological doses used by us they reinforce that local increases in PGE2 participate in 
serum IGF-I transfer to the brain. We then determined whether these mediators require 
MMP-9 to increase IGF-I transcytosis. In the presence of an MMP9 inhibitor (inhMMP9), 
in vitro transcytosis of bhIGF-I  by ATP, PGE2, or EET was abrogated (Figure 7C). As in 
the case of PGE2 this inhibition was not as complete as with the other mediators, it is 
possible that PGE2 recruits additional IGFBP-3 proteases.  
     Thereafter, we confirmed that MMP9 participates in activity-dependent uptake of serum 
IGF-I by the brain in vivo. Infusion of inhMMP9 into the somatosensory cortex of whisker-
stimulated rats blocked the increase in brain interstitial fluid hIGF-I elicited by vibrissae 
stimulation (Figure 4B). Non-specific hemodynamic responses of inhMMP9 were ruled out 
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by infusing it into the somatosensory cortex and determining CBF responses to whisker 
stimulation (Fig S3C). 
     We next conducted an initial characterization of intracellular pathways involved in 
transfer of IGF-I in response to glutamate. We found that addition of a Ca
++
 chelator 
(EGTA) to the culture medium inhibited the stimulatory action of glutamate on IGF-I 
transcytosis through astrocyte-endothelial cells co-cultures, suggesting that the process is 
calcium-dependent (Table 2). Co-addition of thapsigargin, an inhibitor of the ryanodine 
receptor that blocks intracellular Ca
++ 
stores also resulted in abrogation of IGF-I transfer, 
further indicating the involvement of Ca
++ 
fluxes in this process (Table 2). Next, we tested 
various glutamate receptors antagonists and found that inhibition of ionotropic 
AMPA/Kainate receptors with CNQX or of mGluR5 with MPEP abrogated glutamate 
actions whereas NMDA and mGluR1 antagonists (AP5 and Lyly, respectively) did not alter 
the effect of glutamate (Table 2). Further, inhibition of prostanoid synthesis with the Cox 
inhibitor ibuprofen similarly blocked glutamate effects. Finally, no effect on glutamate 
actions was seen after inhibition of purinergic signalling using suramin (Table 2). 
Altogether, these results indicate that non-NMDA ionotropic and GluR5 metabotropic 
glutamate receptors are involved in transfer of IGF-I through astrocyte/endothelial co-
cultures and that prostanoid synthesis is required for this effect.           
     In response to neuronal activation local levels of circulating IGF-I/IGFBP3 will increase 
as a result of increased local blood flow. We postulated that this complex would interact 
with LRP1/IGF-IR at endothelial cells for subsequent transcytosis of IGF-I. Confirming 
observations by others (Huang et al., 2003), we observed that LRP1 interacts with IGFBP3. 
LRP1 was co-immunoprecipitated with IGFBP3 in cell extracts from endothelial cultures 
treated with IGFBP3 (Figure 8A). LRP1 also co-immunoprecipitated with the IGF-I 
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receptor in brain endothelial cells (Figure 8B). Conversely, an HA-tagged mini-LRP1 
(lacking most of the extracellular domain of LRP1) expressed in brain endothelial cells co-
immunoprecipitated with IGF-IR (Figure 8C). This suggested that the interaction between 
LRP1 and IGF-IR does not involve the extracellular ligand-binding domain of LRP1, 
leaving this domain free for binding of extracellular ligands such as IGFBP3. Finally, while 
endothelial cells expressing mini-LRP-1 internalized significantly more bhIGF-I than 
control cells (Figure 8D), HCMEC-D3 endothelioma cells expressing LRP1 siRNA 
internalized markedly less bhIGF-I than scramble siRNA-transfected cells (Figure 8E, F). 
Thus, interaction of LRP-1 with the IGF-I receptor and IGFBP-3 may target the IGF-
I/IGFBP-3 complex to the IGF-I receptor and facilitate the subsequent transcytosis of IGF-I. 
 
Discussion 
     The present results indicate that brain activity drives serum IGF-I input to activated 
areas. This novel link between neuronal activation and localized trophic support appears to 
recruit processes also involved in neuro-vascular coupling (Figure 8G). The fact that 
similar processes participate in allocating nutrient/oxygen supply and at the same time 
trophic support to active brain regions widens the physiological significance of activity-
dependent processes in the brain. Importantly, these observations also provide a regulatory 
mechanism for the neuroactive actions of blood-borne IGF-I.  
     In line with these observations, the increases previously observed in the number of IGF-
I immunoreactive neurons in the developing rat visual cortex after experience-dependent 
neuronal activity (Ciucci et al., 2007), or after environmental enrichment (Guzzetta et al., 
2009) may be explained by localized transfer of serum IGF-I to the brain. Also, higher 
brain activity observed in human subjects with higher serum IGF-I levels (Arwert et al., 
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2005) agree with these findings. Together with recent evidence that neuronal activity 
increases anti-oxidant defences in neurons (Leveille et al., 2010;Papadia et al., 2008), these 
data provide further insight into the neuroprotective effects of neuronal activity.       
     Transcytosis of molecules across the BBB is the most common way to modulate the 
permeability of this barrier (Banks, 2010). Neuronal activity modulates BBB permeability 
through neurovascular coupling. In turn, serum IGF-I participates in brain processes where 
neuronal activity is involved (synaptic plasticity, cognition...etc). Therefore, we reasoned 
that neuronal activity could influence BBB permeability to serum IGF-I. While activity-
driven neuro-vascular and neuro-trophic coupling may share common upstream 
mechanisms such as vasodilation (Figure 8G), downstream mechanisms leading to increase 
glucose uptake and IGF-I transfer respectively, probably diverge. In the former case 
neuronal release of glutamate leads to Ca
++
 fluxes in astrocytes and subsequent release of 
diffusible mediators such as NO, arachidonic acid derivatives, ATP...etc that modulate the 
microcirculation. Eventually, glucose and oxygen uptake are locally enhanced. Glucose 
uptake through the BBB is increased because glucose transporters are translocated to the 
cell membrane in response to a signalling mechanism that is still not well characterized. In 
neuro-trophic coupling, our initial observations suggest that together with vasodilation that 
will increase local availability of circulating IGF-I, glutamate release activates MMP9 in a 
process that appears to recruit several, but not all of the mediators involved in vasogenic 
aspects of neurovascular coupling and that also involves Ca
++
 mobilization. Thus, our 
initial in vitro pharmacological characterization suggest that IGF-I transfer depends on 
ionotropic (AMPA/kainate) and metabotropic (mGluR5) glutamate receptors, arachidonic 
acid derivatives and Ca
++ 
fluxes. However, more work is needed to ascertain the cellular 
and molecular pathways involved. In this regard, it should be noted that after many years of 
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study, the mechanisms underlying neuro-vascular coupling are still under intense scrutiny 
(Shi et al., 2008). 
     At any rate, the present results allow us to propose an overview of the possible processes 
involved. Besides local changes in blood flow (in vivo inhibition of NO blocks IGF-I 
transfer), activation of MMP9 (and other proteases?) by diverse mediators (prostanoids, 
EETs, ATP) appears as the distinct characteristic required in IGF-I transfer across the BBB. 
MMP9 links neuronal activation with transfer of blood-borne IGF-I through an LRP1-
dependent process. A similar process probably takes place at the choroid plexus, where the 
closely related receptor LRP2 also binds to the IGF-I receptor and actively participates in 
IGF-I transcytosis (Carro et al., 2005).  Thus, two parallel processes, neuro-vascular 
coupling, and neuro-trophic coupling, are set in motion by glutamate release at active 
synapses.   
     Several questions remain open. For instance, while the absence of changes in IGF-I 
mRNA synthesis after brain activation suggests that brain activity does not induce local 
IGF-I synthesis, locally activated IGF-I protein translation cannot be ruled out. This 
possibility would require further study. Further, while IGF-I immunoreactivity in the 
nucleus of astrocytes and neurons was already observed by us (Garcia-Segura et al., 1991), 
and more recently confirmed in other cell types (Sehat et al., 2010), the role that IGF-I may 
play in these cellular organelles is still not fully understood.    
     Our observations also provide a mechanistic support for the cognitive reserve hypothesis 
of neuroprotection. Conceivably, neuro-trophic coupling may contribute to the beneficial 
effects of an active social life and higher education on brain function (Fratiglioni et al., 
2004). As neuroprotective behaviors such as exercise or balanced diets also favor entrance 
of serum IGF-I into the brain (Carro et al., 2000;Dietrich et al., 2007) this neuroprotective 
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serum growth factor may be considered a common mediator of the beneficial effects of 
diverse life-style factors on brain health. 
     These findings may help explain disparate observations such as the pro-neurogenic 
effect of epilepsy or electroconvulsive therapy (Kempermann, 2002), the modulatory effect 
of blood flow on neuronal activity (Moore and Cao, 2007), or the rehabilitatory effect of 
neural stimulation (Kaelin-Lang, 2008). The latter may be of particular practical impact. 
The unifying thread in all these processes would be increased input of serum IGF-I to 
stimulated brain regions. In the first case enhanced neurogenesis after neuronal hyper-
activity could be explained by the potent neurogenic effects documented for serum IGF-I 
(Trejo et al., 2008). In the second case, activity-dependent entrance of serum IGF-I coupled 
to enhanced blood flow would conform to the “hemo-neural” hypothesis that proposes that 
diffusible blood-borne messengers modulate neuronal activity (Moore and Cao, 2007).  
Indeed, systemic IGF-I increases neuronal excitability (Nunez et al., 2003) and levels of 
serum IGF-I correlate with brain vascular activation (Arwert et al., 2005). Finally, neural 
stimulation inducing the entrance of systemic IGF-I will in turn produce wide beneficial 
effects on activated areas through the ample neuroprotective actions of IGF-I (Carro et al., 
2003). An unexplored aspect of these observations is the angiogenic role of serum IGF-I 
(Lopez-Lopez et al., 2004). As vessel formation is regulated by tissue demand, activity-
dependent uptake of serum IGF-I through brain vessels would also impinge on vessels 
themselves. Altogether, activity-dependent entrance of a serum neuroprotective factor 
supports the use of neuro-rehabilitation procedures based on targeted neuronal stimulation 
of damaged areas.   
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LEGENDS TO FIGURES 
Figure 1: Active brain areas accumulate systemic IGF-I. A, Electrical stimulation of the rat 
cerebellar peduncle (black bars) increased hIGF-I levels in cerebellum, as compared to 
sham-stimulated rats (white bars). Unstimulated areas such as the cerebral cortex did not 
show differences between stimulated and non-stimulated animals. Rats received hIGF-I 
through the carotid artery before stimulation of the inferior cerebellar peduncle (n=7 per 
group; *p<0.05). B, Electrical stimulation of the rat whiskers increased hIGF-I in the 
contralateral somatosensory cortex in a frequency-dependent fashion. Unilateral vibrissae 
stimulation at 2 Hz activates cortical somatosensory neurons, whereas at 5 Hz stimulation is 
dumped due to neuronal desensitization (inset shows averages of representative vibrissae 
deflection responses at somatosensory cortex; n=10; *p<0.05). Sham: non-stimulated 
animals. C, In 2 Hz-stimulated animals, levels of pTyr IGF-IR were significantly higher in 
the stimulated barrel cortex than in the ipsilateral, non-stimulated side (n=10, **p<0.01). 
Four representative animals (coded 1-4) are shown in blot. Quantitation histograms are 
shown after normalization with total IGF-IR levels (lower blot). Con: control, non-
stimulated side, St, stimulated side. IgGs: band corresponding to the antibody used in 
immunoprecipitation. D,  Hippocampal levels of IGF-I  after 2 hours of enriched housing in 
mice (n= 19-20). E, Hippocampal levels of pTyrIGF-I receptor after environmental 
enrichment. Four representative animals for each group are shown. Levels of pTyr IGF-I 
receptor were normalized with total IGF-I receptor. Densitometric analysis of normalized 
western blots is shown (n= 10; Student´s t-test, **p<0.001). F, Infusion of the IGF-I 
receptor antagonist PPP in the somatosensory cortex during unilateral tactile stimulation of 
the whiskers reduced neuronal activation in contralateral cortex. Upper: peristimulus time 
histograms of a representative S1 cortical neuron to whisker deflection (20 ms duration) in 
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control (left) and after 15 min of PPP (right). Lower: mean tactile responses to whisker 
deflections in S1 cortical neurons. PPP (solid bars), but not the vehicle (empty bars), 
reduced tactile responses (n= 19; **p=0.004).        
 
Figure 2: Neuronal activation triggers entrance of circulating IGF-I. A, Panels a&b: 
digoxigenin immunostaining in somatosensory cortex of whisker-stimulated rats receiving 
an intracarotid injection of digoxigenin-IGF-I prior to stimulation (a); not stimulated rats 
(b). Note the presence of immunostaining in the stimulated side of  the cortex. Dashed area 
indicates somatosensory cortex. No staining is observed in non-stimulated animals. Panel c: 
magnification of the square area in a (stimulated side). Neuronal-like profiles and vessels 
appear stained. M1, primary motor cortex, S1BF, primary sensory cortex barrel field area. 
Panel d: digoxigenin-immunostaining in rat primary sensitive cortex in the area 
corresponding to hind limbs (S1HL) after sciatic nerve stimulation. Panel e: 
immunostaining with anti-digoxigenin shows a Dig-IGF-I accumulating neuron in the 
vicinity of an stained vessel in the somatosensory cortex after sciatic nerve stimulation. 
Panel f: magnification of the same cortical area in a different animal after sciatic nerve 
stimulation. Dig-immunopositive neuron-like cells and vessels are seen. Representative 
animals are shown. B, After whisker stimulation, double immunocytochemistry with anti-
digoxigenin and cell-specific markers denoted co-staining of Dig-IGF-I in endothelial cells 
(tomato lectin
+
 ), astrocytes (GFAP
+) and neurons (β3tubulin
+
) in the stimulated side. A 
small vessel in barrel cortex is shown. Astrocytes surrounding a large vessel are shown. C; 
Panels a&b: digoxigenin immunostaining in the dorsal thalamus of non-stimulated (a) and 
stimulated (b) rats. Panels c&d: magnification of the square areas in a&b. Note the 
increased number of stained neuron-like cells in the stimulated side. VPM, ventral postero-
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medial thalamus, VPL, ventral postero-lateral thalamus, RET, reticular nucleus of the 
thalamus.  D, Stimulated brain areas along the whisker-barrrel cortex pathway accumulate 
Dig-IGF-I. Neuronal activation determined by c-fos staining (green) showed overlapping of 
Dig-IGF-I staining (red) with active regions within this sensory pathway.  Relay areas such 
as the sensitive nucleus of the trigeminal nerve, the lateral thalamus or the primary 
somatosensoty cortex are shown.  
 
Figure 3: Systemically injected Dig-IGF-I localizes in barrel cortex endothelial cells and 
neurons of vibrissae-stimulated rats. A, Electron microscopy photomicrograph of a brain 
endothelial cell showing immunogold staining against digoxigenin in cytoplasm, 
mitochondria, and chromatin. Arrowhead: stained mitochondria in an adjacent cell. B,  
Immunogold staining in the cell nucleus, mitochondria and cytoplasm of a neuron. Inset: 
two labelled mitochondria are shown. M: mitochondria; L: Lumen; BL: Basal lamina. Scale 
bar  A-B: 1 µm, b: 500 nm.   
      
Figure 4: Activity-dependent entrance of circulating IGF-I into the brain. A, Time course 
changes in CBF in barrel cortex during whisker stimulation. Data are averaged at 5 min 
intervals and represented as relative changes versus pre-stimulation values (-10 ~ 0 min).   
* p<0.05 vs. Sham; # p<0.05 vs. 5Hz. B, hIGF-I in insterstitial fluid collected by 
microdyalisis from the somatosensory cortex was detectable only in whisker-stimulated 
animals. Experimental schedule employed in these experiments is shown in the upper panel.  
Infusion of TTX to inhibit neuronal activity in the somatosensory cortex of vibrissae-
stimulated animals abrogated the increase in hIGF-I levels. Infusion of L-NAME to inhibit 
vasodilation also blocked the stimulus-elicited increase in hIGF-I. Infusion of an MMP9 
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inhibitor also resulted in inhibition of the uptake of serum IGF-I. A two-way ANOVA 
revealed a significant interaction (F(8,26)=3.300, p<0.01) and a significant effect of time 
(F(2, 26)=11.80, p<0.001). A post-hoc Tukey’s showed a significant difference between 
baseline and stimulation only in the stimulated group (p<0.01). The stimulated group was 
also significantly different from sham-stimulated (#p<0.05 by Student´s t-test). ○ Sham 
(n=6); ■ stimulated (n=8); ▲stimulated+TTX (n=5); ▼stimulated+L-NAME (n=6); ◊ 
stimulated+MMP9 inhibitor (n=6).    
 
Figure 5: Mechanisms involved in transcytosis of IGF-I across the blood-brain barrier 
(BBB). A, Upper blot: Neurons (Neuro), brain endothelial cells (Endo), and astrocytes 
(Astro) accumulate bhIGF-I in vitro. Lower blots: after eliminating membrane bound 
bhIGF-I with acid wash prior to cell lysis, uptake of bhIGF-I by the 3 types of cells was 
still observed. Endothelial cells appear to take up more IGF-I than either neurons or 
astrocytes, as seen after normalization with βactin. Synthetic bhIGF-I was loaded in the 
right lane. Micrographs: double immunostaining with anti-bhIGF-I and GFAP (astrocytes), 
β3tubulin (neurons) and tomato lectin (endothelium) showed intracellular IGF-I staining in 
the 3 types of cells. B, In a double-chamber well, endothelial/astrocyte co-cultures in the 
upper chamber transport intact bhIGF-I to the lower chamber where neurons internalize it 
as evidenced by the presence of bhIGF-I in neuronal extracts. Scheme of experimental 
arrangement is shown. C, In the presence of active matrix metalloprotease 9 (MMP9a) but 
not inactive (MMP9i), significantly more bhIGF-I was endocytosed by endothelial cells. 
IGFBP-3 inhibited this effect. A similar effect was produced by PSA. **p<0.01 and 
***p<0.001 vs control; n=5. D, IGFBP-3 is produced by endothelial cell cultures. IGFBP-3 
and normal rat serum (NRS, that contains IGFBP-3) were run in parallel as controls. E, 
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Human endothelioma cells transfected with a dominant negative IGF-I receptor (DN-IGF-
IR) endocytosed less bhIGF-I than mock-transfected cells. Representative blot of two 
experiments done in duplicate is shown. Quantitation histograms of internalized bhIGF-I 
shown in the right. Western blots of cell lysates for bIGF-I and IGF-IR/βactin were run 
separately in different membranes (**p<0.01; n=4). F, IGFBP-3 is cleaved by active 
(MMPa), but not inactive MMP9 (MMP9i). Western blot of IGFBP-3 after treatment with 
MMP9 or the vehicle. Intact recombinant IGFBP-3 was run in the right lane. 
 
Figure 6: MMP9 is involved in passage of serum IGF-I across brain endothelium. A, 
Passage of bhIGF-I through astrocytes/brain endothelial cells co-cultures in double-
chamber wells is modulated by IGFBP-3 and MMP9 in an opposite fashion. bhIGF-I and 
IGFBP-3 were placed in the “blood” side (upper chamber) whereas MMP9 was placed in 
the “brain” side (lower chamber). (n= 4; *p<0.05 and **p<0.01 vs lower chamber in 
controls). B, Transcytosis of  bhIGF-I was stimulated by glutamate (100 µM), an effect 
inhibited with an MMP9 inhibitor (10 µM). (n= 7; **p<0.01). C, MMP9 is present in 
endothelial cells (upper zymography and blot) and is stimulated by glutamate in 
endothelial-astrocyte co-cultures (lower zymography). Representative experiments are 
shown (n=2-3). Glut: glutamate, MMPa: active synthetic MMP9 was run as a control.  D, 
Active MMP9 is increased in the stimulated somatosensory cortex. Western blot of MMP9 
in stimulated (stim) and unstimulated (unstim) cortex of the same animal . Recombinant 
MMP9 was run in parallel.  
 
Figure 7: Mediators involved in neuro-vascular coupling modulate passage of blood-borne 
IGF-I across brain endothelium. A, Diffusible mediators released by astrocytes during 
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neuro-vascular coupling stimulated endocytosis of bhIGF-I by brain endothelial cells. 
Prostaglandin E2 (PGE2), epoxyeicosatrienoic acid  (EET), and ATP, but not NO 
(stimulated with SNAP), enhanced IGF-I internalization. Combined addition of the 3  
compounds elicited a similar increase (n=6-10). B, Infusion of PGE2 into the cerebral 
cortex (-0.5 mm from bregma, 1 mm depth) of rats previously receiving an intra-carotid 
injection of Dig-IGF-I results in robust digoxigenin staining in the infused side 30 min later. 
Note that both the contralateral, vehicle-infused side and the brain surface of the injected 
side showed low immunoreactivity attributable to local disruption of the BBB. Three 
consecutive 50 μm brain sections are shown. C, Enhanced internalization of bhIGF-I by 
PGE2, EET, and ATP is inhibited by the MMP9 inhibitor. Note that the drug alone 
decreases bhIGF-I internalization to the same extent, indicating that endogenous MMP9 is 
required to internalize IGF-I (n= at least 3 experiments), ***p<0.001, **p<0.01, and 
*p<0.05 vs control. 
  
Figure 8: The IGF-I receptor interacts with LRP-1 in brain endothelial cells. A, LRP-1 co-
immunoprecipitates with IGFBP-3. Standard IGFBP-3 is shown in the right lane. B,  Co-
immunoprecipitation of LRP1 and IGF-I receptors in brain endothelial cells. An LRP1 band 
was detected only in anti-IGF-I receptor (IGF-IR) immunoprecipitates (IP). Sup: 
supernatants. C, IGF-I receptors (IGF-IR) in brain endothelial cells co-immunoprecipitated 
with an HA-tagged mini-LRP1. Both supernatants (Sup) and immunoprecipitated pellets 
(IP) were assayed in an IGF-IR western blot. Controls included non-transfected cells and 
anti-IGF-IR immunoprecipitated fractions. D, Transfection of brain endothelial cells with 
mini-LRP1 enhanced endocytosis of bhIGF-I (**p<0.01, n= 4). E,F, Transfection of the 
human endothelioma HCMEC-D3 with an LRP1 siRNA resulted in marked inhibition of 
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bhIGF-I internalization. Control cultures were transfected with a scramble shRNA 
sequence. E: Western blots of cell lysates for bIGF-I and LRP1/βactin were run separately 
in different membranes. Two experiments (in duplicate) were loaded/gel. F: Quantitation 
histograms (*p<0.05; n=4). G, Proposed mechanisms involved in serum IGF-I uptake by 
active brain regions. Increased neuronal activaty results in increased blood flow through 
neuro-vascular coupling. The resulting local vasodilation increases the amount of 
circulating IGF-I at the stimulated area. Neuronal activity also stimulates MMP9 activity 
that releases IGF-I from IGFBP3 allowing its internalization through the BBB in an LRP1-
dependent process. Increased IGF-I input in stimulated areas stimulates neuronal activity 
Through this step-wise pathway serum IGF-I could modulate neuronal activity. 
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Experimental procedures 
 
Stimulation protocols. Different types of  brain stimulation protocols were used. In a first 
type rats were anesthetized with urethane (1.1 g/kg i.p.) and the anesthesia maintained with 
intermittent injections (approximately 0.1 g/kg/h). The trachea was cannulated and 
ventilated with ambient air. Body temperature (37⁰C), respiration rate (20 cycles/min) and 
end-tidal CO2 percentage were monitored and controlled. One carotid artery was 
cannulated with PE-50 polyethylene tubing for hIGF-I injection (10 ug/100 grs). Electrical 
stimulation of the inferior cerebellar peduncle was carried out with twisted teflon coated 
wires inserted in the following coordinates: AP: -11 mm; L: 3 mm; DV: 5 mm from the 
surface. Stimulus was a 0.1 ms square pulse (50-100 µA) at 5 Hz frequency. Stimulus 
evoked potentials were recorded in the ipsilateral cerebellum in several animals to confirm 
the stimulation. In a second type of protocol the rat whisker pad was stimulated with two 
subcutaneous electrodes (0.3 mm diameter, stainless steel) located at the dorso-anterior and 
caudo-posterior edges of the whisker pad. Stimulus was a 1ms square pulse applied at twice 
the intensity necessary to elicit visible movement of the whiskers (50-100 µA). Such 
intensity did not induce movement in the whiskers of the contralateral pad. In some 
experiments, stimulus evoked potentials were recorded in barrel cortex at the following 
coordinates: AP: -3 mm from bregma; L: 5 mm from midline; DV: 1 mm from the brain 
surface. In a third type of protocol the whiskers were stimulated by an electronically gated, 
short-lasting air jet (1Kg/ cm2, 20 ms of duration) which could be directed to an individual 
whisker. The control tactile stimulation consisted in pulses lasting 20 ms and delivered at 
0.5 Hz. In an additional protocol animals were anesthesized with urethane (1.6 gr/kg) and 
their sciatic nerve stimulated by exposing the popliteum fosae and delivering pulses of 100 
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s and 0.5 Hz with a square pulse generator (Grass S88). Stimulation intensity was adjusted 
to twice the amount needed to elicit muscle contractions (10-50 A). For sham stimulation, 
electrodes were placed without delivering any current. 
     Behavioral stimulation was produced by placing during 2 hours adult male mice in an 
enriched housing consisting of a large arena containing different toys, plastic tunnels, 
exercise wheels and 10 animals. Non-stimulated animals remained in their standard 
laboratory cages.  
Brain microdialysis.  Rats were anesthetized with sodium pentobarbital (50 mg/kg, ip) and 
fixed to a stereotaxic frame. A guide cannula for microdialysis was placed onto the intact 
duramater above the barrel cortex (coordinates: AP -1.8 mm, L 5.5 mm) contralateral to the 
stimulated whisker pad, and fixed to the skull. After surgery, the rats were housed 
individually and allowed to recover for at least two days. Approximately 24h before the 
experiment, a needle was inserted through the guide cannula to punch the duramater, then a 
microdialysis probe (Eicom, Japan; cutoff of 1,000 kDa; membrane length 2.0 mm; outer 
diameter 0.6 mm) was inserted into the barrel cortex. The probe was infused with artificial 
cerebrospinal fluid (aCSF, Harvard Apparatus, USA) in a push-pull manner with a micro-
pump at 2.5 µl/min. After a 60 min stabilization period, dialysates were collected at 60 min 
intervals for baseline, stimulation, and post-stimulation period (each sample containing 150 
ul dialysate). Five minutes before starting whisker pad stimulation at 2 Hz, hIGF-I (50 
µg/100µl saline) was injected into the carotid artery. The following drugs were used: 
tetradotoxin (TTX, a sodium channel blocker, Tocris, 2 µM), the NO synthase inhibitor, L-
NAME (Tocris, 200 µM) and a MMP-9 inhibitor (Calbiochem, 10 µM). Drugs were 
administered from 60 min before the baseline sampling, and continued throughout the 
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experiment (see FigS3C for an schematic of this protocol). At the end of the experiment, 
the brain was removed and fixed with 4% paraformaldehyde, and cannula placement 
confirmed by histology. The dialysates were stored at -80°C until IGF-I content was 
measured. As circulating hIGF-I could non-specifically enter into the brain through 
disruption of the blood-brain barrier with the microdyalisis probe we checked BBB 
integrity by injecting Evans blue. We observed very limited disruption in the brain surface 
while the area surrounding the tip of the probe remained intact (not shown).  
 
Cell cultures and in vitro assays. Endothelial cell cultures were performed as described 
(Perriere et al., 2007). Briefly, brains were dissected free of meninges on ice and phosphate 
buffer saline (NaCl, 137mM; KCl, 2.7mM; Na2HPO4, 1.5mM), and minced. Brain 
fragments were homogenized and digested for 1.5h at 37ºC in collagenase/dispase (270U 
collagenase/ml, 0.1% dispase) and DNAse (10U/ml) in DMEM. Cells were centrifuged and 
the pellet resuspended  in 20% fetal bovine serum /DMEM (1000g, 15 min) and incubated 
in the collagenase/dispase mixture for 1h at 37ºC. The capillary fragments were retained on 
a 10 μm nylon filter, and endothelial cells removed from the filter with endothelial cell 
basal medium supplemented with 20% fetal bovine serum and antibiotics (penicillin, 100 
U/ml, streptomycin, 100 μg/ml). Cells were seeded in plates coated with collagen type IV 
(5 μg/cm3). Puromycin (3μg/ml) was added for 3 days and replaced by fibroblast growth 
factor (2 ng/ml) and hydrocortisone (500 ng/ml). Astrocyte and neuronal cultures were 
performed as described (Fernandez et al., 2007). Astrocytes were grown in DMEM + 10% 
serum. Co-culture of endothelial cells and astrocytes was performed as described elsewhere 
(Perriere et al., 2007). Three weeks after seeding, astrocytes were trypsinized at 37ºC, 5 
min and seeded (5x104 cells) on collagen VI/fibronectin (0.1 mg/ml and 0.05 mg/ml, 
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respectively)- coated Transwell polyester inserts in DMEM +10% serum. One day after 
seeding, wells were washed and endothelial cells plated on top of the astrocyte layer. 
Endothelial cells were obtained by trypsinizing endothelial cultures four days after initial 
seeding. Under these culture conditions formation of a sealed monolayer mimicking brain 
barrier properties was confirmed by measuring electrical resistance: >100 Ω/cm2, and 
retention of fluorescent dextran in the upper chamber. Human endothelioma HCMEC-D3  
cells were cultured in DMEM-F12 + 10% FCS.  
     Transcytosis assays were performed one week later using biotinylated IGF-I (0.2 μg/ml) 
to distinguish it from endogenously produced IGF-I. bhIGF-I was added to double chamber 
cultures for 1-5 hours before collecting the medium. Internalization assays in cell 
monolayers were performed adding bhIGF-I (0.2 μg/ml) to the respective cultures for 30 
min and washing 3 times with PBS before collection of the cells. To rule out unspecific 
binding of bhIGF-I to cell membranes, cells were exposed to 40 ng/ml of bhIGF-I for 30 
min followed by two washes with 0.1 M PBS pH 6.0 and incubation in EDTA-lysis buffer 
+ protease inhibitors /4ºC for 5 min. Analysis of bhIGF-I content in cells (internalization 
assays) and culture medium (transcytosis assays) was performed by western blot using 
horseradise peroxidase-coupled streptavydin. Transfection of cells with siRNA against 
LRP1, scramble siRNA (Sigma), mini-LRP1, or dominant negative IGF-I receptor was 
carried out with Fugene 6 (Roche). Cells were used 48-72 h after transfection. In 
experiments with inhibitory drugs or IGFBP3, cells were incubated with the different 
compounds 20-60 min prior to the respective experiment. Inhibitory drugs used to assess 
their effects on glutamate-induced IGF-I transfer were added 45 min ahead of glutamate. 
Activation of MMPs was carried out by incubating  at a ratio of 1:10 APMA 10nM (in 
NaOH 0.1M) with the corresponding MMP for 1 hour/37ºC before adding them to the cells. 
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Statistics. A two-way ANOVA was used for overall comparisons and one-way ANOVA for 
intra-group comparisons. Post-hoc tests used included Tukey and Student´s t-test. Statistics 
(microdialysis experiments).  
Please see supplemental information for the following experimental procedures: animals 
and materials, in vivo procedures, cerebral blood-flow measurements, in vivo recordings, 
immunoassays, gel zymography, pre-embedding immunogold labeling and EM, and 
quantitative PCR, 
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Table 1. Changes in arterial blood parameters and body temperature at pre- and post 
stimulations. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Mean SE Mean SE
Control
pH 7.43 0.01 7.43 0.01 n.s.
PCO2 (mmHg) 36.0 1.4 38.2 0.6 n.s.
PO2 (mmHg) 96.2 2.3 94.6 2.8 n.s.
Mean Arterial Pressure (mmHg) 98.5 3.8 100.1 4.4 n.s.
Heart Rate (bpm) 371 6.1 375 6.5 n.s.
Body Temperature (°C) 37.6 0.2 37.7 0.1 n.s.
2Hz
pH 7.44 0.00 7.43 0.01 n.s.
PCO2 (mmHg) 36.3 2.5 38.0 2.4 n.s.
PO2 (mmHg) 89.9 1.7 89.7 5.2 n.s.
Mean Arterial Pressure (mmHg) 93.2 5.9 98.5 3.0 n.s.
Heart Rate (bpm) 349 5.2 358 6.1 n.s.
Body Temperature (°C) 37.7 0.3 37.5 0.2 n.s.
5Hz
pH 7.44 0.01 7.42 0.01 n.s.
PCO2 (mmHg) 38.3 1.0 38.1 0.9 n.s.
PO2 (mmHg) 89.7 3.2 90.2 2.2 n.s.
Mean Arterial Pressure (mmHg) 90.4 4.1 91.4 4.8 n.s.
Heart Rate (bpm) 382 18.8 391 13.2 n.s.
Body Temperature (°C) 37.7 0.2 37.4 0.1 n.s.
n = 4-5. n.s., non significant (paired t-test).
Pre Post
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Table 2. Glutamate-dependent pathways involved in transcytosis of IGF-I across                      
               endothelial-astrocyte co-cultures in double-chamber configuration. 
Treatment IGF-I 
transcytosis
a
 
(% glutamate) 
Statistical 
significance
b
 
Glutamate (n=5) 
Glutamate + AP5 (n=5) 
Glutamate + CNQX (n=5) 
Glutamate + Lyly  (n=5) 
Glutamate + MPEP (n=3) 
Glutamate + Thapsigargin (n=3) 
Glutamate + EGTA (n=3) 
Glutamate + Ibuprofen (n=3) 
Glutamate + Suramin (n=3) 
100 ± 26 
73 ± 31 
55 ± 11 
184 ± 120 
0.3 ± 0.19 
0.2 ± 0.5 
      5.1 ± 0.4   
       53 ± 21 
113 ± 18 
-
 c
 
0.24 
0.001 
0.33 
0.0004 
0.0003 
0.0006        
       0.002 
0.13 
            
            
a 
Mean ± SEM 
                   b
As compared to glutamate (Student´s t-test)
  
 
                   c
Glutamate induced a 217 ± 58% increase in IGF-I transcytosis over                            
              controls (p=0.02). 
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Inventory of supplemental information: Four figures. Figure S1 is related to Figure 1, 
Figure S2 is related to Figure 2, Figure S3 to Figure 4 and S4 to Figure 5. 
Supplementary experimental procedures are also included. 
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                                                        Supplementary Figure 1 
 
Figure S1, related to Figure 1: A, Unilateral whisker pad stimulation did not alter IGF-I 
mRNA levels in the contralateral somatosensory cortex as determined by qPCR. Both the 
stimulated and unstimulated sides show similar IGF-I mRNA levels (n=6). B, Levels of 
hIGF-I in CSF were not altered by electrical stimulation of the whiskers (n=7). C, After icv 
administration of hIGF-I, its levels in CSF were similar in whisker-, and sham-stimulated 
rats (n=7). D, Levels of hIGF-I in somatosensory cortex of stimulated and non-stimulated 
rats previously injected icv with IGF-I. No differences were detected. (n=7).  
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                                                       Supplementary Figure 2 
 
Figure S2, related to Figure 2: Double immunostaining using anti-Dig and anti-IGF-I 
antibodies show that digoxigenin-stained cells in the barrel cortex of a vibrissae-stimulated 
rat contain IGF-I. DAPI staining marks cell nuclei. 
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                                           Supplementary Figure 3 
Figure S3, related to Figure 4: A, Changes in cerebral blood flow (CBF) before and 
during vibrissae stimulation (60 min, solid line). While 2 Hz stimulation produced a 
consistent and significant increase in CBF, stimulation at 5 Hz produced a transient 
significant increase over the first 20 min. Data are averaged at 20 min intervals. * p<0.05, 
**p<0.01 vs. Control, # p<0.05 vs. 5Hz. B, Intracarotid injection of hIGF-I (50 μg/100 µl 
saline) did not alter CBF in the contralateral somatosensory cortex. IGF-I, n=3, saline, n=3. 
C, Infusion of either TTX (2 μM; n=5) or L-NAME (200 μM , n=5) into the barrel cortex 
markedly diminished the increase in CBF by 1 min of 2 Hz stimulation of the contralateral 
vibrissae. Infusion of an MMP9 inhibitor (10 µM, n=3) into the barrel cortex did not 
modify the CBF response to whisker pad stimulation (*p<0.05) 
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                                                  Supplementary Figure 4 
 
Figure S4, related to Figure 5: A, Brain endothelial cells treated with the IGF-I receptor 
antagonist PPP internalized significantly less bhIGF-I than controls. (**p<0.01; n=3). B, 
Treatment of endothelial cells with MMP8 did not increase bhIGF-I internalization by brain 
endothelial cells (n=3). Representative blots are shown. 
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Supplementary Experimental Procedures 
Materials and animals.  Male Wistar rats (225-350 g) and C57BL6J male mice (~30 grs; 
Harlan Labs; Barcelona, Spain) were used. Postnatal (4-7 days) rats were used for cell 
cultures. Animals were kept under standard diet and light/dark conditions following EU 
guidelines and handled according to institutionally-approved procedures. Human 
recombinant IGF-I was from ProSpec-Tany (Israel). Biotinylated IGF-I was from IBT 
(Germany). Digoxigenin-labelled IGF-I was produced following previously published 
procedures (Carro et al., 2000). The IGF-I receptor antagonist picropodophyllin (PPP) was 
from Sigma (USA). Primary antibodies used were: anti-digoxigenin (Roche, Switzerland, 
1:500), anti panIGF-I (1:250, IBT), anti-βactin (1/100,000; Sigma), anti-β3tubulin (1/2,000; 
Promega), anti-GFAP (1/2,000; Dako), and anti-LRP1 (Abcam, USA; recognizing a 37 
KDa fragment of the protein), anti-IGF-IR (Sta. Cruz, USA), anti-pTyr (4G10 Platinum and 
PY20, Millipore, USA), and anti-MMP9 (Abcam), all used at 1:1000 dilution. Tomato 
lectin (1/500, Sigma) was used as a marker of brain endothelia.  Secondary HRP-coupled 
streptavidin was from GE Healthcare (UK; 1:5000), secondary antibodies were from Bio-
Rad (USA; 1/10,000), Alexa-coupled from Molecular Probes, (USA; 1/10,000) or 
biotinylated from Bio-Rad. The following compounds were also used: prostaglandin E2 
(PGE2, 50 µM in vitro and 5 mM in vivo), 11,12 (Sigma) and 8,9 epoxyeicosatrienoic acid  
(EETs, 100 nM, Cayman Chem), ATP (10 nM), SNAP (an NO donor, 150 nM), L-NAME 
(a NO synthase inhibitor, 200 μM), tetrodotoxin (TTX, a sodium channel blocker, 2 μM), 
APMA (an activator of MMP9, 10 mM), MMP9 (50 ng/ml), MMP8 (50 ng/ml), MMP9 
inhibitor (5 nM in vitro and 10 µM in vivo), IGFBP-3 (15 ng/ml), EGTA (10 mM), 
glutamate (100 µM), thapsigargin (ryanodine receptor inhibitor from Tocris, USA; 1 μM), 
Cox inhibitor Ibuprofen (Sigma, 200 µM), suramin (wide spectrum purinergic receptor 
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inhibitor, 100 µM), glutamate receptor inhibitors (Tocris; USA):  AP5 (NMDA, 50 µM), 
CNQX (AMPA/Kainate, 20 µM), Ly367385 (mGluR type 1, 100 µM), MPEP (mGluR5, 50 
μM), and PSA (IGFBP3 protease, 100 ng/ml).  
 
In vivo procedures. hIGF-I was dissolved in saline and administered in the carotid artery 
through a cannula (20-50 µg/100µl saline) or into the brain lateral ventricle (20 µg/5 µl) 
following stereotaxic coordinates: AP: -1 mm from bregma; L: 1,2 mm from midline; DV: 
4 mm from the surface. The IGF-I receptor antagonist PPP (2.5 μM) was dissolved in 
dimethyl sulfoxide whereas PGE2 (5 mM) was dissolved in saline before intracortical 
injection. A microsyringe was lowered 0.5 mm into the primary somatosensory cortex. At 
the end of each experiment, animals were perfused thoroughly with saline. For 
immunocytochemical analysis brains were then handled as indicated below while for 
biochemical determinations brains were quickly removed, and frozen in dry ice; cerebellum 
and olfactory bulb were dissected before freezing the brain. For barrel cortex sampling, the 
remaining frozen brain was cut rostro-caudally using a cryotome in 0.5 mm slices until the 
medial fusion of the anterior commisure (-0.3 mm from bregma). Thereafter a 2 mm slice 
was made and a piece of the barrel cortex isolated through two incisions perpendicular to 
the surface of the cortex at 4.5 and 7 mm from midline. CSF was collected from the 
cisterna magna discarding those samples showing blood contamination. 
 
Cerebral blood flow measurement. Rats were anesthetized with urethane (1.1 g/kg i.p.), and 
the anesthesia maintained with intermittent i.p. injections (~ 0.1 g/kg/h). The animals were 
stereotaxically fixed and a small craniotomy (5 x 5 mm) performed to expose the barrel 
cortex without removing the dura (coordinates: AP -1.5 ~ -2.0 mm; L 5.0 ~ 5.5 mm). 
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Cerebral blood flow (CBF) was continuously monitored using a laser-Doppler flowmeter 
(Omegawave, Japan) during whisker pad stimulation. The time constant was 0.01s. At the 
beginning of the recording the position of the Doppler probe was adjusted to monitor 
consistent and reproducible increases in CBF with brief whisker stimulations at 2Hz. After 
a 60 min stabilization period, the whisker pad was stimulated for 60 min at either 2 or 5 Hz. 
Control animals received sham electrical stimulation. Before and after whisker pad 
stimulation, arterial blood samples were collected and pH, PCO2, and PO2 immediately 
measured using an automated blood gas analyzer (Bayer, USA). Arterial blood pressure 
was continuously monitored and rectal temperature maintained at around 37°C using a 
heating pad (BRC, Japan). Flowmetry data were averaged at 5- or 20-min intervals and 
represented as relative changes versus baseline (recorded for an average of 10 min before 
stimulation).   
 
In vivo recordings. A small hole was drilled in the skull over the SI cortex (50). Unit 
recordings in SI cortex (A 1-3 mm, L 2.5-4 mm from bregma) were recorded at 800 to 
1500 μm below the brain surface using tungsten microelectrodes ; (2-5 M; World 
Precision Instruments, Sarasota, USA). Unit firing was filtered (0.3-3 KHz), amplified 
(DAM80; World Precision Instruments) and fed into a PC computer (sample rate: 8 KHz) 
for off- line analysis with Spike 2 software (Cambridge Electronic Design, Cambridge, UK). 
Cortical field potentials  were recorded at SI cortex, using tungsten macroelectrodes (1 
M). They were filtered (0.3 Hz-1 KHz), amplified and fed into the computer (sample rate: 
3 KHz) Averages of the field potentials and summed peristimulus time histograms (PSTHs; 
2 ms bins) were calculated from 20 stimuli. The mean tactile response was measured from 
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the PSTH as the number of spikes evoked at 10- 50 ms after stimulus onset and divided by 
the number of stimuli (n=20). The IGF-I receptor antagonist PPP (2.5 µM) was dissolved in 
dimethyl sulfoxide before intracortical injection and applied using a microsyringe lowered 
0.5 mm into the primary somatosensory cortex. Data were compared using Student’s paired 
t test and differences were considered statistically significant at the 95% level (p<0.05). 
 
Immunoassays.  hIGF-I was labeled with digoxigenin (Dig; Roche, Switzerland) and 
administered through the carotid artery (10 µg/100 gr). Animals were perfused 
transcardially with saline buffer and 4% paraformaldehyde in 0.1 M phosphate buffer, pH 
7.4. Brain was serially sectioned at 40 µm. Immersed free-floating in 0.1 M phosphate 
buffer sections were assayed for Dig-IGF-I content using a anti-digoxigenin monoclonal 
antibody and/or rabbit anti panIGF-I, anti-GFAP, tomato lectin or anti-β3tubulin. Secondary 
antibodies used were: biotinylated goat anti mouse (1:250, Pierce), alexa-488 conjugated 
donkey anti mouse and alexa-594 conjugated donkey anti rabbit (1: 1000, Molecular 
probes). Biotinylated antibodies were followed by the peroxidase-based ABC system 
(Pierce). In control experiments, first antibodies were omitted and no immunostaining was 
observed for any of the antibodies used (not shown).    
     A commercial hIGF-I ELISA (DSL or R&D Systems, USA) or an in-house rodent IGF-I 
ELISA were used to determine either hIGF-I or murine IGF-I. Lack of cross reactivity with 
rat IGF-I and human IGF-I, respectively was confirmed with rat IGF-I (IBT, Germany) or 
hIGF-I (not shown, but see(Trejo et al., 2007). Frozen brain samples were homogenized in 
1 N acetic acid/4ºC, boiled for 20 min to eliminate the interference with IGF binding 
proteins, lyophilized and reconstituted in assay buffer. Boiled homogenate was centrifuged 
1 min at 14,000 rpm and supernatant was frozen at -80 °C for 1 hour. Frozen protein extract 
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was lyophilized overnight and resuspended in PBS in the minimal volume necessary for 
analyzing IGF-I content in duplicate and total protein content in triplicate. When analyzing 
IGF-I levels in CSF, SEPAK cartridges were used to separate IGF-I from IGFBPs. Frozen 
dialysates were lyophilized and reconstituted with pretreatment buffer to eliminate IGF 
binding proteins interference. 
A commercial ELISA (Cusabio CSB-E07967r)  was used to measure PGE2 levels in 
cortical homogenates of sham-stimulated and vibrissae-stimulated rats following the 
manufacturer´s instructions.  
 
Gel zymography.  MMP-9 proteolytic activity  was assessed by gelatin zymography. 
Endothelial/astrocyte co-cultures were treated with glutamate (100M) or APMA (10mM) 
for 16h in serum-free conditions. Cells were washed three times with PBS and cell lysates 
collected and loaded under no reducing conditions onto gels (10% polyacrylamide , 1% 
gelatin). After electrophoresis, gels were washed twice in 2.5% Triton X-100 for 30 min to 
remove excess SDS and re-nature proteins. Gel were then incubated in developing buffer 
(50mM Tris-HCl,  200mM NaCl and 10mM CaCl2) for 16h at 37ºC. To reveal the 
gelatinolytic activity, gels were stained with 0.25% brilliant blue for 30 min and then 
destained with 10% methanol and 7% acetic acid. Clear zones against the blue background 
indicate the presence of MMP9 proteolytic activity. 
 
Pre-Embedding Immunogold Labeling and EM. Brains were perfused with 0.5% 
glutaraldehyde/2,5% paraformaldehyde and postfixed overnight. Vibratome sections (50 
µm) were cut and blocked in PBS/5% BSA/5% NGS for 30 min, rinsed in incubation buffer 
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(1% BSA-C/PB), and incubated with antibody against digoxigenin (mouse 1:25; Roche 
Diagnostics GmbH) for 48 hr at 4°C. Sections were incubated with secondary antibody 
conjugated to colloidal gold (1:100 Electron Microscopy Sciences) during 24 hours at 4ºC 
and later enhanced with silver, washed, postfixed with 2.5% glutaraldehyde for 20 min, 
washed, and postfixed with 1% osmium tetroxide for 1 hr. Immunostained sections were 
dehydrated and embedded in Durcupan resin (Durcupan ACM; Fluka). Sixty nanometer 
sections were cut and collected on Formvar-coated single-slot grids, stained with uranyl 
acetate and lead citrate, and examined with a FEI Tecnai Spirit electron microscope. 
 
Quantitative PCR. IGF-I qPCR was performed as described (Trejo et al., 2007). Briefly, 
after whisker pad stimulation (2 Hz, 1 hour), animals were perfused with cold saline. The 
brain was rapidly removed and the barrel cortices from both hemispheres dissected and 
snap frozen. Equivalent amounts of isolated total RNA served as template to synthesize 
cDNA using High Capacity cDNA Reverse Transcription Kit (Applied Biosystems, Foster 
City, CA) according to the manufacturer’s instructions. TaqMan probes and primers for 
IGF-I and for the control housekeeping gene, rRNA 18s, were from the Assay-on-Demand 
gene expression products (Applied Biosystems). PCR was performed with the ABI PRISM 
7500 Sequence Detection System (Applied Biosystems, Foster City, CA). The amount of 
IGF-I mRNA was normalized to the endogenous reference and expressed relative to the 
calibrator that was chosen randomly according to the comparative CT method. 
 
 
 
 
 
 
 
